The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
 
Virginia F. Borges
No Relationships to Disclose
 
Arlene Chan
Honoraria - Eisai; Lilly
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Affinia Therapeutics; Aleta Biotherapeutics; Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Denali Therapeutics; Johnson & Johnson/Janssen; Olema Pharmaceuticals; Pfizer; Prelude Therapeutics; Puma Biotechnology; Seagen; Voyager Therapeutics
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
 
Margaret Eleanor Tonda
Employment - Olema Pharmaceuticals
Stock and Other Ownership Interests - Global Blood Therapeutics; Olema Pharmaceuticals
 
Mark Shilkrut
Employment - Olema Oncology; Olema Oncology
Stock and Other Ownership Interests - Novartis
 
Carlos A. Alemany
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)